Miyachi, Kazusa
Iwamoto, Taro
Kojima, Shotaro
Ida, Tomoaki
Suzuki, Junya
Yamamoto, Takuya
Mimura, Norihiro
Sugiyama, Takahiro
Tanaka, Shigeru
Furuta, Shunsuke
Ikeda, Kei
Suzuki, Kotaro
Niewold, Timothy B.
Nakajima, Hiroshi
Article History
Received: 19 December 2022
Accepted: 8 February 2023
First Online: 17 February 2023
Declarations
:
: This study was approved by the Research Ethics Committees of Chiba University Graduate School of Medicine (reference number: 3619/3620) in compliance with the Helsinki Declaration. Patient’s written informed consent was waived according to the local regulations for a retrospective observational study.
: No individual person’s data were presented in any form in this study.
: KI has received research grants from Mitsubishi-Tanabe Pharma and has received honoraria for lectures from Abbvie, Mitsubishi-Tanabe Pharma, Eli Lilly Japan, Novartis, Pfizer Japan, Janssen Pharmaceutical, Eisai, Gilead Sciences and Bristol Myers Squibb, all unrelated to the current manuscript. HN has received research grants from Chugai Pharmaceutical, Abbvie, Takeda Pharmaceutical, Astellas Pharma, Eli Lilly Japan, Asahikasei Pharma, Pfizer Japan, UCB Japan, Eizai, Mitsubishi Tanabe Pharma and Bristol Myers Squibb, and has received honoraria for lectures from Chugai Pharmaceutical, Abbvie, Takeda Pharmaceutical, Astellas Pharma, Eli Lilly Japan, Asahikasei Pharma, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Eisai, Bristol Myers Squibb and Nippon Kayaku, all unrelated to the current manuscript. The other authors have no competing interests to declare.